Diabetes in Mayan Populations: Monitoring of Glycosylated Hemoglobin

玛雅人群糖尿病:糖化血红蛋白监测

阅读:2

Abstract

BACKGROUND: Diabetes mellitus (DM) is a global health concern that has affected various populations worldwide. Among the various methods to monitor the progress and management of DM, glycosylated hemoglobin (HbA(1c)) serves as a key marker for understanding long-term glucose control. The Mayan populations of Yucatan represent a unique demographic in which the prevalence and management of DM can be distinctively analyzed. METHOD: In this study, HbA(1c) levels were monitored over 12 months in 1722 patients with DM from 17 medical units of the Mexican Institute of Social Security in the southern region of Yucatan. Based on initial HbA(1c) levels, patients were assigned to either standard or intensive treatment. Treatment efficacy was analyzed based on sex, age, and location. RESULTS: HbA(1c) levels significantly decreased in patients receiving intensive treatment, from means (±SD) of 9.7±1.9% to 8.9±2.0% after 12 months (P=.001), with notable reductions in remote areas such as Akil and Huntochac (P<.05). Although slight reductions were observed among women and middle-aged individuals, these reductions were not statistically significant (P=.2 and P=.4, respectively). Despite the initial improvement, standard treatment was more effective for maintaining long-term glycemic stability, with lower variability and better adherence. However, a 10% increase in HbA(1c) was observed in this group by the end of the study. CONCLUSION: Monitoring of DM in Mayan populations revealed significant HbA(1c) reductions with intensive treatment, especially in remote areas. Consequently, strategies to improve primary care and promote self-care in DM patients in the Mayan population must be implemented.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。